FOREIGN VALUE: Sanofi-Aventis
Ticker: SNY
Market cap (billions): $96.4
P/E ratio*: 13
Earnings growth**: 4.5%
Dividend yield: 3.1%
Paris-based Sanofi-Aventis is the largest pharmaceutical company in Europe. It has invested heavily in research and development on cardiovascular and diabetes drugs, which has paid off. Sanofi's top drugs include blood-clot treatment Lovenox, blood thinner Plavix and insulin drug Lantus.
While the company's earnings are expected to increase about 4.5% a year for the next few years as it - along with other drugmakers - sees some medications go off patent, this is more than reflected in the stock price. It trades at only 13 times earnings. Plus, it pays a healthy dividend that yields more than 3%.
NEXT: FOREIGN VALUE: Total
Market cap (billions): $96.4
P/E ratio*: 13
Earnings growth**: 4.5%
Dividend yield: 3.1%
Paris-based Sanofi-Aventis is the largest pharmaceutical company in Europe. It has invested heavily in research and development on cardiovascular and diabetes drugs, which has paid off. Sanofi's top drugs include blood-clot treatment Lovenox, blood thinner Plavix and insulin drug Lantus.
While the company's earnings are expected to increase about 4.5% a year for the next few years as it - along with other drugmakers - sees some medications go off patent, this is more than reflected in the stock price. It trades at only 13 times earnings. Plus, it pays a healthy dividend that yields more than 3%.
NEXT: FOREIGN VALUE: Total
-
Abbott Labs -
Coca-Cola -
Colgate-P... -
General M... -
Illinois ... -
Johnson &... -
Procter &... -
US Bancorp -
Accenture -
Chubb -
Cisco Sys... -
McKesson -
3M -
Microsoft -
Parker Ha... -
Walgreen -
Applied I... -
Carlisle ... -
Cascade -
National ... -
Pfizer -
Regal Bel... -
UST -
VF Corp. -
Adtran -
AVX -
Fair Isaac -
Global In... -
Grey Wolf -
Penn Virg... -
Plexus -
Tessera T... -
BP -
Diageo -
Novartis -
Philips E... -
Sanofi-Av... -
Total -
Unilever -
Vodafone ...
Last updated June 20 2008: 2:35 PM ET
RSS Criteria include low price/earnings and price/book ratios relative to competitors, rising profit margins, and accelerating earnings growth.
*Based on previous 12-months' reported earnings. **Wall Street estimates for the next three years.
Source: Zacks Investment Research
*Based on previous 12-months' reported earnings. **Wall Street estimates for the next three years.
Source: Zacks Investment Research
